Abstract

ABSTRACT OF THE DISCLOSURE Novel 6H-dibenz [b,e][1,4] oxathiepin deriva- tives of the formulae I and IA are employed in the treatment and control of allergic conditions such as allergic asthma. I IA wherein n is an integer of from 1-4; Z is thio, sulfinyl, or sulfonyl; R1, R2 and R3 are each independently se- lected from hydrogen, halogen, amino, Cl to C4 alkyl, Cl to C4 alkylthio, Cl to C4 alkylsulfinyl, Cl to C4 alkylsulfonyl, trifluoromethyl, trifluoromethylthio, cyano, nitro, and Cl to C4 alkyl or dialkylamino, Cl to C4 alkoxy, Cl to C4 alkanoyl, aralkyl, or hydroxy Cl to C4 alkyl; R4 is H, Cl to C4 acyl, Cl to C4 alkylamino- acyl, Cl to C4 alkylcarboxy, Cl to C4 alkylcarboxamido, Cl to C4 alkylcarboxamidoacyl or Cl to C4 acyloxy Cl to C4 alkyl; R1 and R2 can also be an unsubstituted C2 to C6 polymethylene chain, or said chain is substituted with a hydroxy or keto group.

IPC Classes  ?

• C07D 327/02 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom